



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes

Policy #: 746

Latest Review Date: February 2022

Category: Lab

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Blue Advantage will treat the **use of maternal serum biomarker tests with or without additional algorithmic analysis** for prediction of preeclampsia as a **non-covered benefit** and as **investigational**.

Blue Advantage will treat the **use of maternal serum biomarker tests with or without additional algorithmic analysis** for prediction of spontaneous preterm birth as a **non-covered benefit** and as **investigational**.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Improved accuracy of the identification of women at risk of preeclampsia and spontaneous preterm birth has the potential to reduce maternal and perinatal morbidity and mortality. Assessment of historical risk and clinical factors represents the traditional approach to diagnosis and planning interventions. Maternal serum biomarker testing is proposed as an adjunct to standard screening to identify women at risk of preeclampsia and spontaneous preterm birth.

Preeclampsia

Preeclampsia is defined as new onset maternal hypertension and proteinuria or new onset hypertension and significant end-organ dysfunction (with or without proteinuria) after the 20th week of gestation. Maternal complications of preeclampsia include progression to eclampsia, placental abruption, and a life-threatening complication known as the hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. In the fetus, preeclampsia can lead to fetal growth restriction and intrauterine fetal death. Preeclampsia can develop in nulliparous women with no known risk factors. Maternal factors associated with an increased risk of preeclampsia include advanced maternal age, presence of a chronic illness such as diabetes mellitus, chronic hypertension, chronic kidney disease, or systemic lupus erythematosus, obesity, multiple gestations, and a prior history of preeclampsia. Preeclampsia can also develop in the postpartum period. In women determined to be at increased risk of developing preeclampsia, the use of daily, low-dose aspirin beginning in the twelfth week of gestation is associated with a reduction in risk and is recommended by the U.S. Preventive Services Task Force (USPSTF) and the American College of Obstetricians and Gynecologists (ACOG). Currently, maternal serum biomarkers are not included in either USPSTF guidelines or ACOG risk factor assessment when determining appropriate candidates for aspirin prophylaxis.

Despite decades of research, accurate identification of women at risk of preeclampsia, particularly prior to the twentieth week of gestation, remains challenging. Standard methods for preeclampsia risk-factor assessment are based on medical and obstetric history and clinical assessment, including routine maternal blood pressure measurement at each prenatal visit. The use of maternal serum biomarker assays as an adjunct to standard preeclampsia risk assessment has been suggested as a mechanism that could improve accurate identification of at-risk individuals. More accurate identification of risk could create an opportunity for additional assessment, surveillance, and interventions that would ultimately reduce the maternal and fetal or newborn morbidity and mortality associated with preeclampsia. Individual maternal serum biomarkers, such as serum placental growth factor (PlGF), soluble Fms-like tyrosine kinase 1 (s-Flt 1), and pregnancy-associated plasma protein A (PAPP-A) have been investigated as predictors of preeclampsia. Multivariable preeclampsia risk assessment tools have been developed that incorporate maternal serum biomarkers; several of these tools have been commercially produced (see Regulatory Status) but few have been externally validated. Clinically useful risk assessment using maternal serum biomarker testing would need to show increased predictive value over standard assessment of preeclampsia risk without serum biomarker testing, resulting in reduced maternal and perinatal morbidity and mortality.

Spontaneous Preterm Birth

Preterm birth is defined as birth occurring between the twentieth and thirty-seventh week of pregnancy and can be spontaneous following preterm labor and rupture of membranes or iatrogenic due to clinical interventions for maternal or fetal medical indications. The preterm birth rate was estimated by the Centers for Disease Control (CDC) to be 10.1% (about 360,000 births were preterm among 3,600,000 births) in 2020 in the United States and has consistently been approximately 10% for over a decade. Preterm birth rates vary according to race and ethnicity independent of social determinants of health, ranging from 8.5% for Asian women to 14.4% for non-Hispanic Black women. Prior preterm birth is the strongest predictor of a subsequent preterm birth, although absolute risk varies according to the gestational age of the prior preterm birth and maternal clinical factors. Characteristics in a current pregnancy that increase the risk of preterm birth include cervical changes (shortened length and/or early dilation), vaginal bleeding or infection, and maternal age under 18 years or over 35 years. Smoking, pre-pregnancy weight, interpregnancy interval, maternal stress, and lack of social support have also been associated with an increased risk of preterm birth. Despite recognition of risk factors, most preterm births occur without clearly identifiable maternal risk factors. Maternal consequences of preterm delivery include intrapartum and postpartum infection. Psychosocial adverse effects including postpartum depression have been reported. Infants born preterm have an increased risk of death up to five years of age relative to full-term infants. Preterm birth is also associated with morbidity extending into adulthood.

Cervical length is one measure available to clinicians to assess risk of preterm birth. Shortened cervical length prior to 24 weeks gestation is associated with an increased risk of preterm birth. The ACOG recommends ultrasonographic assessment of cervical length in the second trimester to identify women at an increased risk of preterm birth.¹ In women with a prior history of preterm birth, serial measurement of cervical length using transvaginal ultrasound is recommended, although optimal timing of measurements has not been clinically established. In women without a history of preterm birth or other risk factors, universal ultrasonographic

screening of cervical length in women has not been demonstrated to be an effective strategy due to the overall low incidence in this group. In women determined to have a shortened cervix and therefore an increased risk of preterm birth, the use of either vaginal or intramuscular progesterone supplementation has been associated with a reduced risk of preterm birth. There are some limitations in assessment of cervical length in predicting risk of preterm birth. These limitations include uncertainty as to what constitutes “shortened” length, with transvaginal ultrasound measurements ranging from <15 mm to <25 mm implicated in indicating increased risk and uncertainty regarding ideal timing of ultrasonographic assessment.

Given the limitations of cervical length assessment in predicting risk of preterm birth, the use of other biomarkers has been suggested as a mechanism that could improve accurate identification of women at risk of preterm birth, including maternal serum biomarkers.

KEY POINTS:

This evidence review was created in February 2022 with a search of the PubMed database. The most recent literature update was performed through December 13, 2021.

Summary of Evidence

For individuals who are pregnant without known risk factors for preeclampsia who receive maternal serum biomarker testing with or without additional algorithmic analysis, the evidence includes systematic reviews of observational studies and a cohort study. Relevant outcomes are test validity, and maternal and perinatal morbidity and mortality. Evidence from two systematic reviews found serum biomarker testing measuring placental growth factor (PIGF) and the soluble Fms-like tyrosine kinase 1 (sFlt-1)/PIGF ratio was associated with high specificity but low sensitivity. Evidence on clinical utility is limited due to lack of randomized controlled trials (RCTs) and heterogeneity among observational studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are pregnant with known risk factors for preeclampsia who receive maternal serum biomarker testing with or without additional algorithmic analysis, the evidence includes systematic reviews of observational studies and cohort studies. Relevant outcomes are test validity, and maternal and perinatal morbidity and mortality. Studies evaluating the predictive ability of maternal serum biomarker testing have found measurement of sFlt-1, PIGF, and the sFlt-1/PIGF ratio can identify women at risk of developing preeclampsia. No RCTs were identified and heterogeneity was high among the observational studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are pregnant without known risk factors for spontaneous preterm birth who receive maternal serum biomarker testing with or without additional algorithmic analysis, the evidence includes a RCT and cohort studies. Relevant outcomes are test validity, and maternal and perinatal morbidity and mortality. Measurement of the insulin-like growth factor binding protein-4 (IBP4) and sex hormone binding globulin (SHBG) ratio demonstrated acceptable discrimination in identifying asymptomatic women who may be at risk of preterm birth, based on

evidence from two industry-sponsored cohort studies. However, a randomized trial did not find a difference in risk of preterm birth with use of the commercially produced PreTRM™ test, which includes the IBP4/SHBG ratio as part of an algorithmic analysis, versus no use. There were also no differences in neonatal outcomes in infants of women who underwent PreTRM testing versus no testing. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are pregnant with known risk factors for spontaneous preterm birth who receive maternal serum biomarker testing with or without additional algorithmic analysis, the evidence includes a systematic review of observational studies. Relevant outcomes are test validity, and maternal and perinatal morbidity and mortality. The systematic review did not identify any individual biomarker that adequately identified women at risk of spontaneous preterm birth based on high sensitivity and specificity. No studies assessing maternal serum biomarkers as part of an algorithmic analysis were identified. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

American College of Obstetricians and Gynecologists and The Society for Maternal-Fetal Medicine

The American College of Obstetricians and Gynecologists (ACOG) issued updated clinical practice guidelines in 2020 on preeclampsia and 2021 on preterm birth. Maternal serum biomarker screening is described as investigational and is not recommended by ACOG as a factor included in risk assessment for either preeclampsia or spontaneous preterm birth.

The 2021 joint ACOG-Society for Maternal-Fetal Medicine (SMFM) guidance on the use of aspirin for prevention of preeclampsia does not include results of maternal serum biomarker testing among the risk factors to be used to identify women at risk of preeclampsia.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force (USPSTF) issued updated recommendations in 2021 on the use of aspirin for the prevention of preeclampsia. The USPSTF does not include maternal serum biomarker testing among factors used in preeclampsia risk assessment. In addition, the recommendation notes "predictive models that combine risk factors to identify pregnant persons at risk for preeclampsia, such as serum biomarkers, uterine artery Doppler ultrasonography, and clinical history and measures, have been developed. However, there is limited evidence from external validation and implementation studies to demonstrate sufficient accuracy of predictive models for clinical use."

KEY WORDS:

Maternal serum biomarker, Preeclampsia, PreTRM, PlGF Preeclampsia Screen, Spontaneous Preterm Birth

APPROVED BY GOVERNING BODIES:

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of these tests. Therefore, maternal serum biomarker tests would be provided by CLIA licensed laboratories.

Commercially produced, maternal serum biomarker tests for preeclampsia include the Triage PIGF™ (Quidel), Elecsys sFlt-1/PIGF™ (Roche Diagnostics), and DELFIA Xpress PIGF 1-2-3™ (PerkinElmer). These commercially produced tests are not currently available in the United States.

The PreTRM™ test (Sera Prognostics) uses maternal serum biomarkers (insulin-like growth factor binding protein-4 [IBP4] and sex hormone binding globulin [SHBG]) in combination with biometric measures to assess the risk of spontaneous preterm birth. According to the manufacturer, the PreTRM test is only intended to be used in women aged 18 years or older, who are asymptomatic (that is, with no signs or symptoms of preterm labor, with intact membranes, and with no first trimester progesterone use) with a singleton pregnancy. The PreTRM test is performed via a single blood draw during the nineteenth week of gestation.

BENEFIT APPLICATION:

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT codes:

0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia
0247U	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth

REFERENCES:

1. Agrawal S, Cerdeira AS, Redman C, et al. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension. Feb 2018; 71(2): 306-316.

2. Agrawal S, Shinar S, Cerdeira AS, et al. Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis. *Hypertension*. Nov 2019; 74(5): 1124-1135.
3. American College of Obstetrics and Gynecology and The Society for Maternal-Fetal Medicine. Practice Advisory: Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. December 2021. Accessed December 16, 2021.
4. Branch DW, VanBuren JM, Porter TF, et al. Prediction and Prevention of Preterm Birth: A Prospective, Randomized Intervention Trial. *Am J Perinatol*. Aug 16 2021.
5. Chaemsaihong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. *Am J Obstet Gynecol*. Jul 16 2020.
6. Cobo T, Kacerovsky M, Jacobsson B. Risk factors for spontaneous preterm delivery. *Int J Gynaecol Obstet*. Jul 2020; 150(1): 17-23.
7. Conde-Agudelo A, Papageorgiou AT, Kennedy SH, et al. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. *BJOG*. Aug 2011; 118(9): 1042-54.
8. Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. *JAMA*. Sep 28 2021; 326(12): 1186-1191.
9. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol*. Jun 2020; 135(6): e237-e260.
10. Hamilton BE, Martin JA, Osterman MJK. Births: Provisional Data for 2020. National Center for Health Statistics. Accessed December 14, 2021.
11. Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. (Evidence Synthesis, No. 205.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK574449/>
12. Honest H, Forbes CA, Duree KH, et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. *Health Technol Assess*. Sep 2009; 13(43): 1-627.
13. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
14. Jackson M, Simhan HN. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. *Obstet Gynecol*. Aug 01 2021; 138(2): e65-e90.
15. Lim S, Li W, Kemper J, et al. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. *Obstet Gynecol*. Jan 01 2021; 137(1): 72-81.
16. Lucaroni F, Morciano L, Rizzo G, et al. Biomarkers for predicting spontaneous preterm birth: an umbrella systematic review. *J Matern Fetal Neonatal Med*. Mar 2018; 31(6): 726-734.
17. Markenson GR, Saade GR, Laurent LC, et al. Performance of a proteomic preterm delivery predictor in a large independent prospective cohort. *Am J Obstet Gynecol MFM*. Aug 2020; 2(3): 100140.

18. Mazaki-Tovi S, Romero R, Kusanovic JP, et al. Recurrent preterm birth. *Semin Perinatol.* Jun 2007; 31(3): 142-58.
19. Mazer Zumaeta A, Wright A, Syngelaki A, et al. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. *Ultrasound Obstet Gynecol.* Sep 2020; 56(3): 400-407.
20. McCarthy FP, Gill C, Seed PT, et al. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study. *Ultrasound Obstet Gynecol.* Jan 2019; 53(1): 62-67.
21. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. *Int J Gynaecol Obstet.* May 2019; 145 Suppl 1: 1-33.
22. Saade GR, Boggess KA, Sullivan SA, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. *Am J Obstet Gynecol.* May 2016; 214(5): 633.e1-633.e24.
23. Sera Prognostics. PreTRM Test for Risk Management. Accessed December 16, 2021. <https://www.pretrm.com/>
24. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Executive summary: Workshop on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation. *Am J Obstet Gynecol.* Sep 2021; 225(3): B2-B7.
25. Townsend R, Khalil A, Premakumar Y, et al. Prediction of pre-eclampsia: review of reviews. *Ultrasound Obstet Gynecol.* Jul 2019; 54(1): 16-27.
26. Veisani Y, Jenabi E, Delpisheh A, et al. Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis. *Int J Reprod Biomed.* Jan 2019; 17(1).

POLICY HISTORY:

Adopted for Blue Advantage, February 2022

Medical Policy Group, February 2022

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.